Quest Diagnostics (NYSE:DGX) had its price target lowered by stock analysts at Credit Suisse Group from $103.00 to $101.00 in a research note issued on Tuesday. The brokerage presently has an “outperform” rating on the medical research company’s stock. Credit Suisse Group’s price target points to a potential upside of 13.56% from the stock’s current price.
Several other equities analysts have also recently weighed in on the company. Canaccord Genuity reaffirmed a “buy” rating and issued a $97.00 price objective on shares of Quest Diagnostics in a report on Monday. Zacks Investment Research raised Quest Diagnostics from a “sell” rating to a “hold” rating in a report on Monday. Mizuho set a $106.00 price objective on Quest Diagnostics and gave the company a “buy” rating in a report on Friday, February 15th. UBS Group set a $91.00 price objective on Quest Diagnostics and gave the company a “hold” rating in a report on Friday, February 15th. Finally, Barclays reaffirmed a “buy” rating and issued a $114.00 price objective on shares of Quest Diagnostics in a report on Friday, February 15th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and nine have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $102.82.
Shares of NYSE DGX opened at $88.94 on Tuesday. The firm has a market capitalization of $11.95 billion, a price-to-earnings ratio of 14.10, a P/E/G ratio of 1.84 and a beta of 0.89. The company has a quick ratio of 0.87, a current ratio of 0.94 and a debt-to-equity ratio of 0.65. Quest Diagnostics has a fifty-two week low of $78.95 and a fifty-two week high of $116.49.
Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings data on Thursday, February 14th. The medical research company reported $1.36 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.37 by ($0.01). The company had revenue of $1.84 billion during the quarter, compared to analyst estimates of $1.88 billion. Quest Diagnostics had a net margin of 9.77% and a return on equity of 15.23%. Quest Diagnostics’s revenue was down 1.4% on a year-over-year basis. During the same period in the prior year, the firm earned $1.40 earnings per share. As a group, equities research analysts forecast that Quest Diagnostics will post 6.46 EPS for the current fiscal year.
Several institutional investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. bought a new stake in Quest Diagnostics during the 3rd quarter worth $743,000. USS Investment Management Ltd grew its position in Quest Diagnostics by 3.0% during the 4th quarter. USS Investment Management Ltd now owns 103,300 shares of the medical research company’s stock worth $8,603,000 after acquiring an additional 3,000 shares during the last quarter. CenturyLink Investment Management Co grew its position in Quest Diagnostics by 10.3% during the 4th quarter. CenturyLink Investment Management Co now owns 12,861 shares of the medical research company’s stock worth $1,071,000 after acquiring an additional 1,196 shares during the last quarter. Tdam USA Inc. grew its position in Quest Diagnostics by 9.4% during the 4th quarter. Tdam USA Inc. now owns 7,236 shares of the medical research company’s stock worth $603,000 after acquiring an additional 622 shares during the last quarter. Finally, Legacy Financial Advisors Inc. bought a new stake in Quest Diagnostics during the 4th quarter worth $45,000. 85.73% of the stock is owned by institutional investors.
About Quest Diagnostics
Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services.
Recommended Story: Do Tariffs Work?
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.